Joslin Diabetes Center, Inc.

Joslin Diabetes Center, Inc. is a Boston-based nonprofit research and clinical institution that serves as the prime recipient on federal research grants focused on diabetes pathophysiology, prevention, and treatment, with secondary activity as a sub-recipient in collaborative multi-site studies funded by the National Institutes of Health. The organization does not hold federal contracts but operates almost entirely within the federal research-grant ecosystem, receiving $30.1 million in combined potential value across 230 recent awards, of which 83 percent are prime grants and 17 percent are sub-awards to larger research consortia.

Joslin's research portfolio centers on mechanistic diabetes science and translational work: beta-cell senescence and function in Type 1 and Type 2 diabetes, insulin signaling and glucose homeostasis, diabetic complications including kidney disease and cardiovascular complications in long-duration Type 1 diabetes, metabolic health and obesity mechanisms, and clinical interventions for diabetes technology adoption and glycemic control in adolescents and young adults. Representative prime grants include a $1.92 million National Institute on Aging project grant evaluating cognitive decline and Alzheimer's disease markers in individuals with 50-plus years of Type 1 Diabetes (awarded September 2025, completion May 2030), an $826,321 National Institute of Diabetes and Digestive and Kidney Diseases cooperative agreement to develop therapeutic strategies targeting renalase for early-stage Type 1 Diabetes (awarded April 2026, completion March 2028), and a $150,583 NIDDK project grant examining molecular drivers of insulin resistance and sex-specific glucose uptake alterations (awarded September 2025, completion July 2028). Joslin also participates in multi-site consortia as a sub-recipient, including the Kidney Precision Medicine Project, Type 1 Diabetes TrialNet, and the Immune Tolerance Network's ITN095AI clinical trial.

Customer concentration is extreme: 91 awards accounting for $19.4 million combined potential value flow through the National Institute of Diabetes and Digestive and Kidney Diseases, representing approximately 64 percent of all prime and sub awards and 64 percent of combined potential value. The National Institutes of Health broadly (including NHLBI, NICHD, and National Institute on Aging) funds 84 percent of Joslin's award count. The Indian Health Service provided two awards valued at $5.7 million combined. Activity has grown from nine awards in 2022 to twenty in 2024, with 2025 maintaining momentum at seventeen awards. Joslin faces recompete exposure on twenty-three awards completing within the next twenty-four months. As a prime, Joslin frequently sub-contracts work to academic medical centers and research institutes; recent sub-award partnerships include the University of Massachusetts Medical School (collaborative metabolomics and immune-system analysis), Brigham and Women's Hospital (neuroimaging analysis for cognitive decline studies), Beth Israel Deaconess Medical Center (proteomic profiling and clinical trial coordination), and The Broad Institute (platform development for beta-cell delivery and production). The organization operates as a 501(c)(3) nonprofit and does not compete under federal contracting set-asides; its federal footprint is entirely research-grant driven, with no presence in GWACs, IDIQs, or government-wide acquisition vehicles.